Company: CERO
Filing Date: 2025-07-14
Form Type: 424B3
Source: 0001213900-25-063764
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-14
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)

Registration No. 333-283492

Prospectus Supplement No. 5

(To Prospectus dated May 23, 2025, as supplemented by

Prospectus Supplement No. 1, dated June 6, 2025

Prospectus Supplement No. 2 dated June 16, 2025

Prospectus Supplement No. 3 dated June 25, 2025

Prospectus Supplement No. 4 dated July 2, 2025)

<div align='center'>CERO THERAPEUTICS HOLDINGS, INC.

2,100,000 Shares of Common Stock</div>

This prospectus supplement no. 5 (this “Prospectus
Supplement”) amends and supplements the prospectus dated May 23, 2025 (as may be supplemented or amended from time to time, the
“Prospectus”), which forms part of our Post-Effective Amendment No. 1 to Registration Statement on Form S-1 (Registration
Statement No. 333-283492). This Prospectus Supplement is being filed to update and supplement the information included or incorporated
by reference in the Prospectus with the information contained in the attached Current Reports on Form 8-K, filed with the Securities and
Exchange Commission (the “Securities and Exchange Commission”) on July 8, 2025 and on July 14, 2025 (collectively, the “Form
8-Ks”). Accordingly, we have attached the Form 8-Ks to this Prospectus Supplement.

This Prospectus Supplement updates and supplements
the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus,
including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if
there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus
Supplement.

Our common stock and public warrants are listed on
Nasdaq Capital Market (“Nasdaq”) under the symbols “CERO” and “CEROW,” respectively. On July 11, 2025,
the last quoted sale price of our common stock as reported on Nasdaq was $8.72 per share and the last quoted sale price of our public
warrants as reported on Nasdaq was $0.0186 per warrant.

We are